Welcome to our dedicated page for Acrivon Therapeutics SEC filings (Ticker: ACRV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Acrivon Therapeutics, Inc.’s SEC filings document the formal disclosures of a Nasdaq-listed clinical-stage biotechnology company focused on precision oncology. Its 8-K reports cover results of operations, financial condition, Regulation FD presentations, pipeline updates for ACR-368 and ACR-2316, and disclosures related to its internal CLIA-certified laboratory and companion diagnostic activities.
The company’s proxy materials describe annual meeting matters, board elections, auditor ratification, executive and director governance, and stockholder voting procedures. Filing records also identify the company’s common stock registration on Nasdaq and provide exhibits that support business updates, clinical program presentations, material agreements, and risk-related public-company reporting.
Acrivon Therapeutics described interim Phase 2b data for its CHK1/2 inhibitor ACR-368 in endometrial cancer during a company-sponsored key opinion leader panel held at the ESGO Congress. The trial uses the ACR-368 OncoSignature biomarker to prospectively select patients predicted to benefit.
In the biomarker-positive Arm 1, ACR-368 monotherapy showed an objective response rate of 39% (95% CI, 24–56) in 31 treated subjects, with disease control rate of 80.6% and 16‑week clinical benefit rate of 61.3%. Across arms, better response rates were observed in patients with ≤2 prior lines of therapy, including serous and non‑serous histologies.
Safety data showed mainly hematologic adverse events such as thrombocytopenia, anemia, leukopenia and neutropenia, with no fatal treatment-related events and a notable absence of common non‑hematologic toxicities. The study is expanding to additional U.S. and European sites, with enrollment completion for the serous all‑comer cohort targeted in Q4 2026.
Acrivon Therapeutics reported an insider tax-related share disposition involving its President and CEO, Dr. Peter Blume-Jensen. The company withheld 14,265 shares of common stock at $1.53 per share to cover mandatory taxes due on vested restricted stock units, rather than an open-market sale. After this withholding, Dr. Blume-Jensen directly holds 2,080,204 common shares. The filing also notes 314,127 common shares held indirectly in spousal accounts shared between Dr. Blume-Jensen and co-founder and EVP Dr. Kristina Masson, with each spouse disclaiming beneficial ownership beyond their economic interest.
Acrivon Therapeutics, Inc. Chief Accounting Officer Katharine Peterson reported a small tax-related share disposition. On the vesting of restricted stock units, 116 shares of common stock were withheld by the company to satisfy mandatory tax withholding, valued at $1.63 per share. After this withholding, Peterson directly holds 4,006 shares of Acrivon common stock.
Acrivon Therapeutics, Inc. Chief Legal Officer Mary Miller reported a routine share disposition related to taxes. On the transaction date, 217 shares of common stock were withheld by the company at a price of $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. After this tax-withholding disposition, she held 33,679 shares of common stock directly.
Acrivon Therapeutics, Inc. Chief Development Officer Erick Gamelin reported a tax-related share disposition. On February 14, 2026, the issuer withheld 471 shares of common stock at $1.63 per share to satisfy mandatory tax withholding upon vesting of restricted stock units. This reduced Gamelin’s directly held common stock to 14,812 shares. The transaction is classified as a disposition for tax withholding, not an open-market purchase or sale.
Acrivon Therapeutics Chief Operating Officer Eric Devroe reported a small tax-related share disposition. On the vesting of restricted stock units, 723 shares of common stock were withheld by the company at a price of $1.63 per share to cover mandatory tax withholding. After this non-market transaction, Devroe directly holds 74,585 shares of Acrivon Therapeutics common stock.
Acrivon Therapeutics insiders reported tax-related share dispositions tied to restricted stock unit vesting. The filing shows 1,302 shares of Common Stock disposed at $1.63 per share, leaving 2,094,469 shares owned following this transaction.
A separate indirect transaction reports a tax-withholding disposition of 579 Common Stock shares at $1.63 per share, with 314,127 shares owned indirectly afterward. Footnotes explain shares were withheld by the issuer to satisfy mandatory tax withholding and that certain holdings are through a spouse, with each spouse disclaiming beneficial ownership beyond their pecuniary interest.
Acrivon Therapeutics, Inc. insider Mary Miller, the company’s Chief Legal Officer, reported a routine share withholding related to equity compensation. On 01/17/2026, 659 shares of common stock were withheld at a price of $1.98 per share to cover mandatory tax withholding when her restricted stock units vested. After this transaction, she beneficially owned 33,896 shares of Acrivon common stock, held directly. This type of transaction does not represent an open-market sale but an automatic tax-related adjustment.
Acrivon Therapeutics’ President and CEO, Dr. Peter Blume-Jensen, reported buying 49,000 shares of common stock on January 14, 2026, in an open-market purchase at a weighted average price of $1.676 per share. The trades were executed in multiple lots at prices ranging from $1.66 to $1.68 per share. Following this transaction, he directly holds 2,095,771 common shares.
The filing also reports 314,706 common shares held indirectly through co-founder and EVP Dr. Kristina Masson. Footnotes state that Dr. Masson disclaims beneficial ownership of Dr. Blume-Jensen’s directly held shares, and Dr. Blume-Jensen likewise disclaims beneficial ownership of Dr. Masson’s shares, except to the extent of each spouse’s pecuniary interest.
Acrivon Therapeutics, Inc. Chief Financial Officer Adam D. Levy reported an open-market purchase of the company’s common stock. On January 14, 2026, he bought 8,832 shares of Acrivon common stock in a series of trades at a weighted average price of $1.6983 per share, with individual trade prices ranging from $1.695 to $1.7086. Following this transaction, he beneficially owned 20,983 shares of Acrivon common stock, held in direct ownership.